Biotech Movers: Geron Corporation (NASDAQ:GERN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Gilead Sciences (NASDAQ:GILD)

Geron Corporation (NASDAQ:GERN) on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat. Geron Corporation (NASDAQ:GERN) stock performance was 4.01% in last … Continue reading Biotech Movers: Geron Corporation (NASDAQ:GERN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Gilead Sciences (NASDAQ:GILD)

Volatile Stocks: Prosensa Holding (NASDAQ:RNA), 22nd Century Group Inc (NYSEMKT:XXII), Alnylam Pharmaceuticals (NASDAQ:ALNY), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

Prosensa Holding NV (NASDAQ:RNA) was upgraded by stock analysts at KBC Securities from a “hold” rating to an “accumulate” rating in a report issued on Wednesday. The firm currently has a $11.00 price objective on the stock, up from their previous price objective of $7.00. KBC Securities’ target price would indicate a potential upside of 1.57% from the company’s current price. Prosensa Holding NV (NASDAQ:RNA) … Continue reading Volatile Stocks: Prosensa Holding (NASDAQ:RNA), 22nd Century Group Inc (NYSEMKT:XXII), Alnylam Pharmaceuticals (NASDAQ:ALNY), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)

ArQule, Inc (NASDAQ:ARQL) CEO Paolo Pucci purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was purchased at an average cost of $1.42 per share, with a total value of $7,100.00. Following the transaction, the chief executive officer now directly owns 232,280 shares of the company’s stock, valued at approximately $329,838. ArQule, Inc. (NASDAQ:ARQL) stock performance was -2.76% … Continue reading New Lows: ArQule, Inc. (NASDAQ:ARQL), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), TrovaGene Inc (NASDAQ:TROV)

Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova Therapeutics Inc (NASDAQ:ONTX) for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova Therapeutics Inc (NASDAQ:ONTX) has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get … Continue reading Biotech Stocks Touched New Lows: Onconova Therapeutics Inc (NASDAQ:ONTX), Array Biopharma (NASDAQ:ARRY), AVEO Pharmaceuticals (NASDAQ:AVEO), Infinity Pharmaceuticals (NASDAQ:INFI)

FDA publicly (justifiably) took down AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) when patients on its drug survived less long than those in the control group. Novo Nordisk found itself years behind competitors because the FDA insists on a heart safety study of its new insulin. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -3.21% in last session and finished the day at $1.51. Traded volume was 730,784.00million shares … Continue reading Biotech New Lows: AVEO Pharmaceuticals (NASDAQ:AVEO), Onconova Therapeutics (NASDAQ:ONTX), BioTime (NYSEMKT:BTX), Tetralogic Pharmaceuticals (NASDAQ:TLOG)

Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) wants to start life with a new slate. It has taken several measures to wipe out the old issues. The company took care of two major worries. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock performance was 10.43% in last session and finished the day at $5.93. Traded volume was 1.14 million shares in the last session and the average volume of … Continue reading Healthcare Overbought Stocks: Pernix Therapeutics Holdings (NASDAQ:PTX), AVEO Pharmaceuticals (NASDAQ:AVEO), WellPoint Inc. (NYSE:WLP), Horizon Pharma (NASDAQ:HZNP)